AVLN Avalyn Pharma Inc. - common stock
NASDAQ · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 12, 2026AVLN Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
AVLN Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | AVLN | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/B (MRQ) | 3.1 | · | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Data fundamental belum cukup untuk menghitung grup rasio ini.
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | AVLN | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | 0.0 | · | · | · | |
| Rasio Lancar (MRQ) | 33.1 | · | · | · | |
| Utang Jangka Panjang / Ekuitas (MRQ) | 0.0 | · | · | · |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Data fundamental belum cukup untuk menghitung grup rasio ini.
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Data fundamental belum cukup untuk menghitung grup rasio ini.
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | $-0.98 | $-0.83 | -18.6% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Neraca
| Metrik | Tren | 2025 |
|---|---|---|
| Cash & Equivalents | $52M | |
| Short-term Investments | $86M | |
| Prepaid Expense | $5M | |
| Current Assets | $144M | |
| PP&E (Net) | $792.0K | |
| PP&E (Gross) | $846.0K | |
| Accum. Depreciation | $54.0K | |
| Other Non-current Assets | $3M | |
| Total Assets | $149M | |
| Accounts Payable | $4M | |
| Accrued Liabilities | $10M | |
| Current Liabilities | $14M | |
| Capital Leases | $1M | |
| Total Liabilities | $15M | |
| Common Stock | $24.0K | |
| Retained Earnings | $-265M | |
| AOCI | $134.0K | |
| Stockholders' Equity | $-239M | |
| Liabilities + Equity | $149M | |
| Shares Outstanding | 1,227,186 |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| R&D Expense | $25M | $23M | $18M | $15M | |
| SG&A Expense | $7M | $5M | $4M | $3M | |
| Operating Expenses | $31M | $28M | $22M | $19M | |
| Operating Income | $-31M | $-28M | $-22M | $-19M | |
| Interest Income | $3M | $1M | $2M | $1M | |
| Other Non-op | $-69.0K | $13.0K | $-41.0K | $-35.0K | |
| Income Tax | $0 | $0 | $0 | $0 | |
| Net Income | $-29M | $-27M | $-20M | $-18M | |
| EPS (Basic) | $-0.98 | $-21.83 | $-17.63 | $-63.24 | |
| EPS (Diluted) | $-0.98 | $-21.83 | $-17.63 | $-63.24 | |
| Shares (Basic) | 29,650,660 | 1,230,698 | 1,145,309 | 276,792 | |
| Shares (Diluted) | 29,650,660 | 1,230,698 | 1,145,309 | 276,792 | |
| EBITDA | $-31M | $-28M | · | · |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $264M | $92M | · | · | |
| Short-term Investments | $88M | $31M | · | · | |
| Prepaid Expense | $6M | $7M | · | · | |
| Current Assets | $358M | $130M | · | · | |
| PP&E (Net) | $1M | $1M | · | · | |
| PP&E (Gross) | $1M | $1M | · | · | |
| Accum. Depreciation | $216.0K | $117.0K | · | · | |
| Other Non-current Assets | $3M | $3M | · | · | |
| Total Assets | $425M | $136M | · | · | |
| Accounts Payable | $3M | $3M | · | · | |
| Accrued Liabilities | $7M | $8M | · | · | |
| Current Liabilities | $11M | $12M | · | · | |
| Capital Leases | $1M | $1M | · | · | |
| Total Liabilities | $27M | $28M | · | · | |
| Long-term Debt | $15M | $15M | · | · | |
| Total Debt | $15M | $15M | · | · | |
| Common Stock | $67.0K | $24.0K | · | · | |
| Retained Earnings | $-321M | $-292M | · | · | |
| AOCI | $-95.0K | $12.0K | · | · | |
| Stockholders' Equity | $398M | $-264M | · | · | |
| Liabilities + Equity | $425M | $136M | · | · | |
| Shares Outstanding | 44,333,094 | 1,232,442 | · | · |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Stock-based Comp | $3M | $1M | $1M | $543.0K | |
| Operating Cash Flow | $-26M | $-30M | $-21M | $-19M | |
| CapEx | $269.0K | $318.0K | $0 | $8.0K | |
| Investing Cash Flow | $-119M | $55M | $-37M | $24M | |
| Stock Issued | · | $50M | · | · | |
| Net Stock Activity | · | $50M | · | · | |
| Financing Cash Flow | $317M | $15M | $90M | $0 | |
| Free Cash Flow | · | $-30M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | -13.6% | -39.6% | · | · | |
| ROE | -14.5% | 20.3% | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 33.1 | 11.0 | · | · | |
| Quick Ratio | 32.6 | 10.4 | · | · | |
| Debt / Equity | 0.0 | -0.1 | · | · | |
| LT Debt / Equity | 0.0 | -0.1 | · | · |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Book Value / Share | $8.99 | $-214.41 | · | · | |
| Cash Flow / Share | · | $-24.29 | · | · | |
| Cash / Share | $5.96 | $74.90 | · | · |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $1.46B | · | · | · | |
| Enterprise Value | $1.12B | · | · | · | |
| P/B | 3.7 | · | · | · | |
| P / Tangible Book | 3.7 | · | · | · |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Data fundamental belum cukup untuk membuat laporan ini.
Data fundamental belum cukup untuk membuat laporan ini.
Data fundamental belum cukup untuk membuat laporan ini.
Aktivis & pemilik 5%+ 2 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| SR One Capital Management, LLC, SR One Capital Fund II Aggregator, LP, SR One Capital Partners II, LP, AMZL, LP, SR One Capital SMA Partners, LP, Simeon George | 8 Mei 2026 | 7,50% | Pengajuan awal | Investasi pasif | SEC |
| SUVRETTA CAPITAL MANAGEMENT, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., Aaron Cowen | 8 Mei 2026 | 5,60% | Pengajuan awal | Kampanye dewan | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 14 orang dalam · 5 pejabat · 7 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Lyn Baranowski | Chief Executive Officer | 29 April 2026 A | · | 0 | 0 | $0 |
| Douglas R Carlson | Chief Financial Officer | 30 April 2026 A | · | 0 | 0 | $0 |
| Melissa Rhodes | Chief Operating Officer | 29 April 2026 A | · | 0 | 0 | $0 |
| Adam H. Golden | General Counsel | 29 April 2026 A | · | 0 | 0 | $0 |
| Howard Lazarus | Chief Medical Officer | 29 April 2026 A | · | 0 | 0 | $0 |
| Robert J. Meyer | Direktur | 15 Sep. 2026 A | · | 0 | 0 | $0 |
| Jill Carroll | Direktur | 1 Mei 2026 C | 2.186.562 | 1 | 0 | $5.000.004 |
| Erin Lavelle | Direktur | 30 April 2026 A | · | 0 | 0 | $0 |
| Kate Haviland | Direktur | 29 April 2026 A | · | 0 | 0 | $0 |
| Jon Congleton | Direktur | 29 April 2026 A | · | 0 | 0 | $0 |
| Heather D Turner | Direktur | 29 April 2026 A | · | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Pemilik 10% | 1 Mei 2026 C | 1.275.486 | 0 | 0 | $0 |
| FMR LLC | Pemilik 10% | 1 Mei 2026 C | 2.284.535 | 0 | 0 | $0 |
| Novo Holdings A/S | · | 1 Mei 2026 C | 3.883.289 | 1 | 0 | $9.999.990 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 15 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| IWO · iShares Trust | 0,03% | 110.766 SH | 11 Sep. 2026 | Harian |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 2.408 SH | 1 Okt. 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 98.545 SH | 19 Agu 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 12.713 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,02% | 435.913 SH | 11 Sep. 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 192.602 SH | 19 Agu 2026 | Harian |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 4.638 SH | 19 Agu 2026 | Harian |
| WSML · iShares Trust | 0,01% | 1.433 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,00% | 6.744 SH | 3 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 534.440 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 1.442 SH | 19 Agu 2026 | Harian |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Juli 2026 | Harian |
| IWN · iShares Trust | · | 48.795 SH | 11 Sep. 2026 | Harian |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15 Juli 2026 | Harian |
| ISCB · iShares Trust | · | 852 SH | 11 Sep. 2026 | Harian |
AVLN Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
Target Harga 12 Bulan
4 analis · 2026-09-28Target rata-rata $62.25 +121,3%
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| AVLN | · | · | · | · | · | · |
| INVA | · | 6.1 | 14.7% | · | · | · |
| PAHC | · | 12.9 | 17.1% | 6.6% | 29.7% | 33.8% |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
| LBRX | $563M | -7.1 | · | · | -25.5% | · |
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.